Safety, tolerability, and feasibility [clinicaltrials_resource:2c2947b22fab7ae6dd19486d550b753e]

Safety, tolerability, and feasibility [clinicaltrials_resource:2c2947b22fab7ae6dd19486d550b753e]

Clinical trial summary from the National Cancer Institute's PDQ® database
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:2c2947b22fab7ae6dd19486d550b753e
Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers [clinicaltrials:NCT00095862]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Safety, tolerability, and feasibility [clinicaltrials_resource:2c2947b22fab7ae6dd19486d550b753e]

Clinical trial summary from the National Cancer Institute's PDQ® database
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:2c2947b22fab7ae6dd19486d550b753e
Bio2RDF identifier
2c2947b22fab7ae6dd19486d550b753e
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2c2947b22fab7ae6dd19486d550b753e
measure [clinicaltrials_vocabulary:measure]
Safety, tolerability, and feasibility
description
Clinical trial summary from the National Cancer Institute's PDQ® database
identifier
clinicaltrials_resource:2c2947b22fab7ae6dd19486d550b753e
title
Safety, tolerability, and feasibility
@en
inDataset
type
label
Safety, tolerability, and feas ...... 947b22fab7ae6dd19486d550b753e]
@en